MedBioGene licenses technology to Precision

Vancouver's MedBioGene Inc (MBI) has finalized its commercialization, licence and research reimbursement agreement with Precision Therapeutics Inc, Pittsburgh, giving Precision exclusive global rights to commercialize its technology. LungExpressDX is a proprietary gene expression-based test to improve the identification of patients with early-stage, non-small-cell lung cancer with a higher risk of mortality following the removal of tumors. The technology is being developed by a teams of researchers at Princess Margaret Hospital/ University Health Network and led by Drs Frances Shepherd and Ming-Sound Tao. MBI is focused on the development and commercialization of gemomic-based personalized laboratory tests….